Mr Jason Lillich, CSW-PIP, QMHP | |
11 4th Street East, Lemmon, SD 57638 | |
(605) 374-3862 | |
(605) 374-3864 |
Full Name | Mr Jason Lillich |
---|---|
Gender | Male |
Speciality | Social Worker - Clinical |
Location | 11 4th Street East, Lemmon, South Dakota |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1821593005 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1041C0700X | Social Worker - Clinical | 4762 (South Dakota) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Jason Lillich, CSW-PIP, QMHP Po Box 447, Lemmon, SD 57638 Ph: (605) 374-3862 | Mr Jason Lillich, CSW-PIP, QMHP 11 4th Street East, Lemmon, SD 57638 Ph: (605) 374-3862 |
News Archive
The New Scientist reports on a software program that is being used "to identify a high correlation between the time and place where people tweet they have dengue and the official statistics for where the disease appears each season."
When Speaker Nancy Pelosi unveiled the revised House Democratic health care bill last week, the Obama White House hailed it as a "critical milestone" in the process. No doubt senior administration officials were relieved to see signs of "momentum" toward passage of something. But if the president really meant what he has said about health care policy throughout this year, his administration would be working to defeat the Pelosi bill, not supporting it (James Capretta).
Roll Back Malaria Partners are supporting mass distribution of malaria bednets to prevent hundreds of thousands of deaths from malaria in many endemic countries.
A new study offers hope for patients with recurrent lung cancer, who historically have been considered ineligible for curative treatment. In the largest analysis to date of reirradiation using intensity-modulated proton therapy for lung and other thoracic tumors, more than three-fourths of patients were free from local recurrence at one year following retreatment, and fewer than one in ten patients experienced severe side effects.
WaferGen Biosystems, Inc., a leading developer of state-of-the-art genomic analysis systems, and NuGEN Technologies, Inc., a leader in innovative genomic samples preparation, today announced they will co-develop and co-market simple, seamlessly integrated workflows for gene expression profiling and target enrichment to enable researchers to more easily achieve high-throughput, high-density real-time PCR with small, degraded, and hard-to-replace clinical specimens, such as formalin fixed paraffin embedded tissue (FFPE).
› Verified 1 days ago